In Massachusetts, TEPHA Inc. completed a buy-out of its royalty obligation to Metabolix, Inc., its former licensor and parent company. TEPHA develops implantable medical devices based on biomaterials, including a biologic polymer called poly4hydroxybutyrate (P4HB) which is made through a fermentation process. Andrew Joiner, President and CEO of Tepha, told PR Newsire “The buy-out of our royalty obligation in conjunction with Metabolix was financially advantageous for both companies. Specifically for Tepha, the cash flow from our savings will help finance the continued development of our core technology as well as pre-clinical and clinical testing of new applications.” TEPHA plans on using its P4HB-based fibers to expand into collagen, antibiotic coatings and non-woven materials in new markets.
Latest article
Edible bowls: The new taco shell?
In South Africa, a startup has created edible bowls to reduce plastic waste. Munch Bowls, founded by Georgina de Kock in 2014, sells bowls made...
Two friends quit jobs, create leather alternative made from cactus
In Mexico, two entrepreneurs have developed a biodegradable, vegan leather from cactus, which they named Desserto. Friends Adrian Lopez Velarde and Marte Cazarez began...
Bioplastic is an “apeeling” solution to banana waste
In Queensland, researchers at the University of New South Wales have developed a process to convert banana waste into plastic.
Associate Professor Jayashree Arcot and...